# A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of AST-120 (Kremezin) in Patients With Moderate to Severe CKD

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-multicenter-randomized-double-blind-placebo-controlled-dose-ranging-study-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Gerald Schulman,Rajiv Agarwal,Muralidhar Acharya,Tomás Berl,Samuel S. Blumenthal,Nelson Kopyt |
| Citations | 198 |
| DOI | 10.1053/j.ajkd.2005.12.036 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2133991735 |
| PMID | 16564934 |
| Type | article |
| Year | 2006 |

## Paper authors

- [Samuel S. Blumenthal](https://scholariq.org/researchers/samuel-s-blumenthal/)

## Paper journal

- [American Journal of Kidney Diseases](https://scholariq.org/journals/american-journal-of-kidney-diseases/)

## Paper primary topic

- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)

## Paper topics

- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Coffee research and impacts](https://scholariq.org/topics/coffee-research-and-impacts/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.